Luye claims its first FDA approval, for bi-weekly schizophrenia drug

Luye claims its first FDA approval, for bi-weekly schizophrenia drug

Source: 
Pharmaphorum
snippet: 

China’s Luye Pharma has claimed its first FDA approval, getting a green light for Rykindo, an injectable formulation of the antipsychotic risperidone given every two weeks.